| Texas Heart Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Texas Heart Institute designates this educational activity for a maximum of 5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Estimated Study Time
The estimated time to complete this activity, including review of the materials is 5 hours. Repurposing Statement
If you previously completed and received credit for the live CME-sponsored symposium entitled, 8th Texas Update in Cardiovascular Advancements on July 25-26, 2008, please note that you will not receive credit for completing this activity. Participants who take part in an identical activity, even in order to validate learning or to clarify specific topics, cannot claim, nor will the Texas Heart Institute award, duplicate credit for the activity.
Term of Approval
October 15, 2008 through October 15, 2011. Continuation of CME credit from October 15, 2011 depends upon a thorough review of the content for currency and accuracy. Peer Review
In October 2008, this continuing medical education activity was reviewed for currency and accuracy of content by Patrick J. Hogan, MD, FACC, Director Learning Resource Center and Co-Chairman, Medical Education Committee, Texas Heart Institute, Houston, TX. Disclosure of Relationships
It is the intent of the Texas Heart Institute to ensure that its educational mission and its continuing medical activities in particular, should not be influenced by the special interests of individuals associated with its program. Faculty Disclosure
In accordance with the guidelines of the Accreditation Council for Continuing Medical Education, faculty members have disclosed their relationships, either with one or more of the manufacturers of commercial products discussed, or with one or more of the corporate organizations offering educational grants for the live continuing medical education activity. Benjamin Cheong, MD does not have any disclosures relevant to this program.
Jose Diez, MD discloses the following, relevant to this program: Consultant—sanofi-aventis.
Mauro Ferrari, PhD discloses the following, relevant to this program: Consultant—Leonardo Biosystems, Inc., NanoMedical Systems, and Arrowhead Research Institute; Stockholder and Officer—Leonardo Biosystems, Inc. and NanoMedical Systems; Research grants—NanoMedical Systems; Scientific advisor—Arrowhead Research Institute.
R. David Fish, MD does not have any disclosures relevant to this program but will discuss unlabeled or investigational use of products.
O.H. Frazier, MD discloses the following, relevant to this program: Consultant—Thoratec Corporation.
Scott M. Grundy, MD, PhD discloses the following, relevant to this program: Consultant--Eli Lilly and Company, sanofi-aventis, Daiichi Sankyo Co., Ltd., Merck & Co., Inc., Liposcience, Inc. and Aegerion Pharmaceuticals, Inc.
Douglas L. Mann, MD discloses the following, relevant to this program: Research grants-- National Institutes of Health; Consultant--Acorn Cardiovascular, Inc. and Medtronic, Inc.; Scientific advisory board--ARMGO Pharma Inc., LPath, Inc., Nile Pharmaceuticals, and Cardiokine.
AJ Marian, MD does not have any disclosures relevant to this program, but will discuss unlabeled or investigational uses of products.
Ali Massumi, MD does not have any disclosures relevant to this program but will discuss unlabeled or investigational use of products.
James T. Willerson, MD does not have any disclosures relevant to this program.
In addition, the peer reviewer, Patrick J. Hogan, MD has nothing to disclose relevant to this program.
| 
